Monte Rosa Therapeutics, Inc.
GLUE
Positions held
Your positionsGLUE isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $880.43M | Enterprise value | $297.32M | Trailing P/E | — | Forward P/E | -5.30 |
| PEG | — | Price / book | 1.81 | Beta | 1.37 | Dividend yield | 0.00% |
| Revenue growth | -61.3% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -5.5% |
| Profit margin | 0.0% | ROE | -42.7% | ROA | -21.6% | Debt / equity | 0.08 |
| Current ratio | 10.58 | Free cash flow | -$74.45M | Analyst recommendation | strong_buy | Mean target | $28.00 |
| 52w high | $25.77 | 52w low | $8.53 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $9.0M | $4.2M | $2.8M | $12.8M | $23.2M |
| Op margin | -547.8% | -1188.5% | -1787.7% | -258.3% | -67.1% |
| Net income | -$43.4M | -$44.5M | -$46.1M | -$27.1M | -$12.3M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$49.1M | -$50.0M | -$49.7M | -$33.0M | -$15.6M |
- Revenue +113% vs prior quarter ($9.0M vs $4.2M).
- Operating margin expanded to -547.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $124M | $75.6M | $0.0M | $0.0M | — |
| Op margin | -43.8% | -107.3% | — | — | — |
| Net income | -$38.6M | -$72.7M | -$135M | -$109M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$54.2M | -$81.1M | -$143M | -$112M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
2026-10-02 · Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 · Sector Update: Healthcare Stocks Decline Premarket Thursday
2026-10-01 · Sector Update: Healthcare
2026-10-01 · Monte Rosa Therapeutics Says MRT-8102 Showed Biomarker Improvements in Phase 1 Study
2026-10-01 · HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target
2026-09-13 · Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone
2026-09-08 · Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon
2026-09-08 · Monte Rosa to Receive $50 Million Milestone Payment From Novartis for Phase 2 Launch of MRT-6160
Price (daily)
Full chart · RSI · MACD · patterns